Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

24.56 -1.15 (-4.47%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 Next >

Unusual volume stocks in Wednesday's session ↗

January 07, 2026

Via Chartmill

XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025)

December 13, 2025

XOMA Corporation (Nasdaq: XOMA), operating as XOMA Royalty Corporation since July 2024, has undergone a profound strategic metamorphosis, transitioning from a traditional biopharmaceutical developer to...

Via PredictStreet

Topics Intellectual Property

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗

October 17, 2025

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.

Via Stocktwits

Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality

October 17, 2025

October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of...

Via MarketMinute

Topics Intellectual Property Workforce

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗

September 30, 2025

Via Stocktwits

Mural Oncology To Be Acquired By Xoma Royalty ↗

August 20, 2025

Via Stocktwits

XOMA Revenue Jumps 39% in Fiscal Q2 ↗

August 13, 2025

Via The Motley Fool

Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps ↗

June 27, 2025

XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right.

Via Stocktwits

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

May 28, 2025

Via Benzinga

The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts ↗

March 28, 2025

Via Benzinga

Forecasting The Future: 5 Analyst Projections For XOMA Royalty ↗

February 03, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts ↗

December 03, 2024

Via Benzinga

Demystifying XOMA: Insights From 5 Analyst Reviews ↗

July 09, 2024

Via Benzinga

Peeling Back The Layers: Exploring XOMA Through Analyst Insights ↗

May 31, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For XOMA ↗

April 29, 2024

Via Benzinga

XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024 ↗

August 13, 2024

XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base ↗

July 09, 2024

FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.

Via Benzinga

3 Crazy Good Stocks to Buy With $500 Right Now ↗

June 12, 2024

For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.

Via InvestorPlace

XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 ↗

March 08, 2024

XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Recap: XOMA Q4 Earnings ↗

March 08, 2024

Via Benzinga

XOMA's Return On Capital Employed Insights ↗

May 24, 2023

Via Benzinga

Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma ↗

February 16, 2024

XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 01, 2023

On Friday, 57 companies reached new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

August 28, 2023

During Monday, 102 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 27, 2023

During Thursday, 56 stocks hit new 52-week lows.

Via Benzinga

Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst ↗

June 22, 2023

Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and...

Via Benzinga

Recap: XOMA Q1 Earnings ↗

May 09, 2023

XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 26, 2023

Wednesday saw 59 companies set new 52-week lows.

Via Benzinga

XOMA: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

Headline News about XOMA Royalty Corporation - Common Stock